Innovative Antiviral Focus Evrys Bio specializes in antiviral therapeutics targeting sirtuins, which offer a broad approach to treating multiple viral infections such as hepatitis B and C. This innovative focus presents opportunities for partnerships with healthcare providers and organizations seeking advanced, resistance-proof antiviral solutions.

Recent Government Funding With over $50 million in non-dilutive government funding and multiple awards from the Department of Defense, Evrys Bio demonstrates strong financial backing and recognition, indicating potential for expanded collaborations, research grants, and contract opportunities in the biotech and government sectors.

Strategic Event Engagements Evrys Bio actively participates in prestigious biopharma summits and government conferences, such as the East-West Biopharma Summit and NIH events, providing numerous avenues for business development outreach and network expansion with key industry and government stakeholders.

Early Stage Revenue Potential With current revenues estimated between $10M and $25M and ongoing clinical and research projects, Evrys Bio is poised for growth. Businesses offering complementary technologies or services may find opportunities to collaborate in drug development, manufacturing, or distribution channels.

Growing Market and Funding Reach Evrys Bio’s recent financing success and high-profile research initiatives suggest a company in expansion mode, which can benefit from strategic partnerships, licensing agreements, and supply chain collaborations as it advances its antiviral candidates toward commercialization.